文献速递炎症性肠病消化道肿瘤与早癌消化内镜

炎症性肠病高级别异型增生后结直肠癌高风险

High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients.
PubMed 文献 · Aliment Pharmacol Ther · 2025-10-24

这项荷兰全国性回顾性队列研究纳入1991至2021年1220例结肠炎症性肠病合并高级别异型增生患者,28.5%诊断为结直肠癌,其中16.7%为同步癌;1016例非同步患者中14.2%发生异位结直肠癌,中位3.6年,1、5、10年累积发生率分别为2.9%、9.9%、15.5%,异位肿瘤累积发生率分别为18.3%、51.2%、68.0%。

要点

  • 高级别异型增生后结直肠癌风险高,需重视同步癌排查
  • 异位结直肠癌10年累积发生率达15.5%,异位肿瘤达68.0%
  • 保留结肠治疗需权衡异位结直肠癌风险并加强内镜监测

核心结论

  • 炎症性肠病高级别异型增生患者同步和异位结直肠癌风险均高,属高危人群。

研究设计与样本

  • 荷兰全国性回顾性队列研究,从PALGA数据库提取1991至2021年结肠炎症性肠病合并高级别异型增生患者1220例。

主要发现

  • 1220例中348例(28.5%)诊断结直肠癌,其中204例(16.7%)在首次高级别异型增生诊断后6个月内诊断,视为同步癌。
  • 1016例非同步患者中144例(14.2%)发生异位结直肠癌,中位时间3.6年。
  • 高级别异型增生后异位结直肠癌1、5、10年累积发生率分别为2.9%、9.9%、15.5%。
  • 异位肿瘤1、5、10年累积发生率分别为18.3%、51.2%、68.0%。
  • 高级别异型增生后免直肠结肠切除术生存率随时间下降。

临床怎么用

  • 对炎症性肠病高级别异型增生患者应警惕同步结直肠癌,确诊后短期内需充分评估。
  • 选择保留结肠治疗时需权衡异位结直肠癌高风险,并坚持严格内镜监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on colorectal cancer (CRC) risk after high-grade dysplasia in inflammatory bowel disease. AIMS: To determine the long-term CRC and neoplasia risk after a first diagnosis of high-grade dysplasia in inflammatory bowel disease, and to assess utilisation of high-grade dysplasia treatment strategies over the past three decades. METHODS: In this nationwide retrospective cohort study, patients with colonic inflammatory bowel disease and high-grade dysplasia diagnosis between 1991 and 2021 were extracted from the Dutch nationwide pathology databank (PALGA). The primary outcome was the cumulative incidence of metachronous CRC. Kaplan-Meier curves were used to show proctocolectomy-free survival per decade. RESULTS: CRC was diagnosed in 348 of 1220 patients (28.5%). Of these, 204 (16.7%) were diagnosed with CRC within 6 months after the first high-grade dysplasia diagnosis and were considered synchronous patients. Metachronous CRC was diagnosed in 144 of 1016 patients (14.2%) after a median of 3.6 years. The 1-, 5- and 10-year cumulative incidences of metachronous CRC after high-grade dysplasia were 2.9%, 9.9% and 15.5%, respectively. The 1-, 5- and 10-year cumulative incidences of metachronous neoplasia were 18.3%, 51.2% and 68.0%, respectively. Proctocolectomy-free survival after high-grade dysplasia decreased over time. CONCLUSIONS: The risk of synchronous and metachronous CRC after a diagnosis of high-grade dysplasia underlines the high-risk profile of this subgroup of patients with inflammatory bowel disease. The possible advantages of colon-sparing treatment should be balanced with the higher risk of metachronous CRC and the subsequent need for stringent endoscopic surveillance.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Derks MEW, Te Groen M, Derikx LAAP, et al. High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients. Aliment Pharmacol Ther. 2025. PMID: 41132006. doi:10.1111/apt.70429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。